Pelthos Therapeutics Inc.
No enriched coverage for $PTHS in the last 7 days.
No SEC Form 4 filings for $PTHS in the last 30 days.
See all $PTHS insider activity →Pelthos Therapeutics reported Q2 2026 net product revenue of $15.4M, up 45% from Q1. ZELSUVMI prescriptions rose 48% to 11,925 units. Adjusted EBITDA loss narrowed to $5.7M. The company has $24.2M in cash and plans to launch XEPI and Xeglyze in 2027. COGS included a $900K inventory write-off, and SG&A had a $5.3M milestone payment.
Pelthos Therapeutics reported Q2 2026 progress for ZELSUVMI, citing a 48% rise in prescription units and an 81.3% unit increase tied to a late-2025 PBM contract. The company expects gross-to-nets to move from 29.6% toward mid-30% and projects XEPI launch in Q1 2027 and Xeglyze in Q3 2027. It also noted a $0.9M inventory write-off and a $5.3M one-time milestone payment.
Pelthos Therapeutics Inc. (PTHS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pelthos Therapeutics Announces Second Quarter 2026 Financial Results Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescr
Recent PTHS coverage spans earnings, financial news and insider activity.
Revenue surge and improved gross-to-net margins suggest upside potential, while continued net loss and cash burn temper expectations.
Pelthos Therapeutics reported Q2 2026 progress for ZELSUVMI, citing a 48% rise in prescription units and an 81.3% unit increase tied to a late-2025 PBM contract. The company expects gross-to-nets to move from 29.6% toward mid-30% and projects XEPI launch in Q1 2027 and Xeglyze in Q3 2027. It also noted a $0.9M inventory write-off and a $5.3M one-time milestone payment.
Q2 revenue acceleration and a new senior secured term loan improve near-term funding visibility, but losses and rising SG&A remain key risk factors.
Insider buying can be a modest sentiment tailwind, but it is not a fundamental catalyst by itself.
Conference participation is typically a low-volatility catalyst unless accompanied by new clinical/commercial datapoints or guidance.
AlphAI scores every news story that mentions PTHS with an AI model for sentiment and relevance, and aggregates insider trades from Pelthos Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pelthos Therapeutics reported Q2 2026 net product revenue of $15.4M, up 45% from Q1. ZELSUVMI prescriptions rose 48% to 11,925 units. Adjusted EBITDA loss narrowed to $5.7M. The company has $24.2M in cash and plans to launch XEPI and Xeglyze in 2027. COGS included a $900K inventory write-off, and SG&A had a $5.3M milestone payment.
3 min readPelthos Therapeutics reported Q2 2026 progress for ZELSUVMI, citing a 48% rise in prescription units and an 81.3% unit increase tied to a late-2025 PBM contract. The company expects gross-to-nets to move from 29.6% toward mid-30% and projects XEPI launch in Q1 2027 and Xeglyze in Q3 2027. It also noted a $0.9M inventory write-off and a $5.3M one-time milestone payment.
6 min readPelthos Therapeutics Inc. (PTHS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pelthos Therapeutics Announces Second Quarter 2026 Financial Results Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescr
6 min readDavis Todd C purchased 35,948 shares of Pelthos Therapeutics Inc. (PTHS) at an average of $27.82 ($27.80–$28.73, $1.00M total) across 2 trades on 2026-06-11.
1 min readPelthos Therapeutics Inc. (NYSE American: PTHS) said CEO Scott Plesha will present at 11:05 a.m. ET and take part in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. The company noted investors can arrange meetings via their Jefferies representative.
2 min readFrancis Knuettel II (CFO, Treas & Secty) sold (to issuer) 13,947 shares of Pelthos Therapeutics Inc. (PTHS) on 2026-05-22.
1 min readDURHAM, N.C., Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Pelthos Therapeutics Inc. PTHS, a biopharmaceutical company ( "Pelthos" or the "Company" ) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel II, ...
3 min readZelsuvmi cleared all molluscum lesions in 33% of patients vs. 19.7% on placebo by week 12 in 891-patient trial. Zelsuvmi is FDA-approved for at-home use in adults and children as young as one year old. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the ...
4 min read
